Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART

被引:30
作者
Lehmann, Clara
Daeumer, Martin
Boussaad, Ibrahim
Sing, Tobias
Beerenwinkel, Niko
Lengauer, Thomas
Schmeisser, Norbert
Wyen, Christoph
Faetkenheuer, Gerd
Kaiser, Rolf
机构
[1] Univ Cologne, Dept Internal Med, Cologne, Germany
[2] Univ Cologne, Inst Virol, Cologne, Germany
[3] Max Planck Inst Informat, Saarbrucken, Germany
[4] Univ Calif Berkeley, Dept Math, Berkeley, CA 94720 USA
关键词
HIV; chemokine receptors; virus tropism; HAART failure; resistance;
D O I
10.1016/j.jcv.2006.08.008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Disease progression in HIV infection has been associated with switch of viral coreceptor usage from CCR5 to CXCR4. Objectives: To investigate the relationship between HIV-coreceptor tropism and clinical and virological outcome in 40 heavily pretreated patients over time. Methods: Coreceptor phenotype was predicted after sequencing the V3 loop of the HIV glycoprotein 120. Results: Coreceptor use was stable during observation time in 87% of patients, and CCR5 tropism was predominant. Viral mutations in the pol gene and clinical parameters were not predictive for coreceptor switching. Conclusions: Even in patients with repeated HAART failure, CCR5 antagonists might be a valuable treatment option. ((c))2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:300 / 304
页数:5
相关论文
共 18 条
[1]   Geno2pheno:: estimating phenotypic drug resistance from HIV-1 genotypes [J].
Beerenwinkel, N ;
Däumer, M ;
Oette, M ;
Korn, K ;
Hoffmann, D ;
Kaiser, R ;
Lengauer, T ;
Selbig, J ;
Walter, H .
NUCLEIC ACIDS RESEARCH, 2003, 31 (13) :3850-3855
[2]   A new classification for HIV-1 [J].
Berger, EA ;
Doms, RW ;
Fenyö, EM ;
Korber, BTM ;
Littman, DR ;
Moore, JP ;
Sattentau, QJ ;
Schuitemaker, H ;
Sodroski, J ;
Weiss, RA .
NATURE, 1998, 391 (6664) :240-240
[3]   BIOLOGIC FEATURES OF HIV-1 THAT CORRELATE WITH VIRULENCE IN THE HOST [J].
CHENGMAYER, C ;
SETO, D ;
TATENO, M ;
LEVY, JA .
SCIENCE, 1988, 240 (4848) :80-82
[4]   R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy [J].
Delobel, P ;
Sandres-Sauné, K ;
Cazabat, M ;
Pasquier, C ;
Marchou, B ;
Massip, P ;
Izopet, J .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (04) :382-392
[5]   Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 [J].
Fätkenheuer, G ;
Pozniak, AL ;
Johnson, MA ;
Plettenberg, A ;
Staszewski, S ;
Hoepelman, AIM ;
Saag, MS ;
Goebel, FD ;
Rockstroh, JK ;
Dezube, BJ ;
Jenkins, TM ;
Medhurst, C ;
Sullivan, JF ;
Ridgway, C ;
Abel, S ;
James, IT ;
Youle, M ;
van der Ryst, E .
NATURE MEDICINE, 2005, 11 (11) :1170-1172
[6]  
FENYO EM, 1989, AIDS S1, V3, P5
[7]   SIMPLE DETERMINATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SYNCYTIUM-INDUCING V3 GENOTYPE BY PCR [J].
FOUCHIER, RAM ;
BROUWER, M ;
BROERSEN, SM ;
SCHUITEMAKER, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (04) :906-911
[8]   Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences [J].
Jensen, MA ;
Li, FS ;
van't Wout, AB ;
Nickle, DC ;
Shriner, D ;
He, HX ;
McLaughlin, S ;
Shankarappa, R ;
Margolick, JB ;
Mullins, JI .
JOURNAL OF VIROLOGY, 2003, 77 (24) :13376-13388
[9]   Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection [J].
Koot, M ;
vantWout, AB ;
Kootstra, NA ;
deGoede, REY ;
Tersmette, M ;
Schuitemaker, H .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) :349-354
[10]   Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults [J].
Lalezari, J ;
Thompson, M ;
Kumar, P ;
Piliero, P ;
Davey, R ;
Patterson, K ;
Shachoy-Clark, A ;
Adkison, K ;
Demarest, J ;
Lou, Y ;
Berrey, M ;
Piscitelli, S .
AIDS, 2005, 19 (14) :1443-1448